| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/CLPT.1984.256 |
| P698 | PubMed publication ID | 6499356 |
| P2093 | author name string | G R Wilkinson | |
| P J Wedlund | |||
| R A Branch | |||
| C B McAllister | |||
| W S Aslanian | |||
| P433 | issue | 6 | |
| P921 | main subject | drug metabolism | Q1124842 |
| P304 | page(s) | 773-780 | |
| P577 | publication date | 1984-12-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism | |
| P478 | volume | 36 |
| Q73980913 | A rapid electron-capture gas chromatographic procedure for the analysis of p-hydroxymephenytoin |
| Q46621528 | Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry |
| Q72329911 | Analysis of mephenytoin, 4-hydroxymephenytoin and 4-hydroxyphenytoin enantiomers in human urine by cyclodextrin micellar electrokinetic capillary chromatography: simple determination of a hydroxylation polymorphism in man |
| Q40648534 | Assessment of liver metabolic function. Clinical implications |
| Q46856522 | Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity |
| Q43952641 | Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype |
| Q27005916 | CYP2C19 polymorphism influences Helicobacter pylori eradication |
| Q35825603 | CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy |
| Q41931375 | Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. |
| Q41925505 | Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail |
| Q28201086 | Clinical significance of the cytochrome P450 2C19 genetic polymorphism |
| Q34398035 | Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation |
| Q44545173 | Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? |
| Q71993387 | Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status |
| Q34346631 | Debrisoquine and mephenytoin oxidation in Sinhalese: a population study |
| Q46621426 | Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype |
| Q51432740 | Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. |
| Q35545117 | Development of analytical technology in pharmacogenetic research. |
| Q71691491 | Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole |
| Q41143951 | Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. |
| Q40174260 | Early effects of oral administration of omeprazole and roxatidine on intragastric pH. |
| Q71378053 | Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study |
| Q41906399 | Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects |
| Q46459661 | Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes |
| Q43222504 | Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine |
| Q51580305 | Ethnic and genetic determinants of omeprazole disposition and effect. |
| Q37268522 | Ethnic differences in drug disposition and responsiveness |
| Q35200922 | Family studies of mephenytoin hydroxylation deficiency |
| Q57586052 | Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations |
| Q43204632 | Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population |
| Q43932932 | GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin |
| Q36244452 | Genetic Aspects of Drug Disposition and Therapeutics |
| Q43071574 | Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group. |
| Q71809352 | Genetic analysis of the S-mephenytoin polymorphism in a chinese population* |
| Q48064742 | Genetic analysis of the cytochrome P-45OIIC18 (CYP2C18) gene and a novel member of the CYP2C subfamily |
| Q81183094 | Genetic polymorphism analysis of cytochrome P4502C19 in Chinese Uigur and Han populations |
| Q28242387 | Genetic predisposition to drug-induced hepatotoxicity |
| Q60486806 | Genetic variation at the CYP2C locus and its association with torsemide biotransformation |
| Q80220331 | Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs |
| Q44947499 | Genetically determined polymorphisms in drug oxidation |
| Q71724815 | Genotype analysis of the CYP2C19 gene in the Japanese population |
| Q28270486 | Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19 |
| Q34403760 | High clearance of (S)-warfarin in a warfarin-resistant subject |
| Q77407649 | Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19 |
| Q39063283 | In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme |
| Q42796114 | In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19) |
| Q71497705 | In vivo and in vitro measurement of CYP2C19 activity |
| Q35137054 | Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution |
| Q34357273 | Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin |
| Q51599922 | Interethnic difference in omeprazole's inhibition of diazepam metabolism* |
| Q41138049 | Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype |
| Q38616806 | Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations. |
| Q34347232 | Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19 |
| Q34735634 | Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits |
| Q36458584 | Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase |
| Q60678424 | Lack of effect of mianserin on the symptoms of diabetic neuropathy |
| Q34358059 | Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies |
| Q90537627 | Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine |
| Q34397680 | Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark |
| Q73924025 | Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis |
| Q42285121 | Mephenytoin hydroxylation in the Cuna Amerindians of Panama |
| Q73369049 | Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status |
| Q74058615 | Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype |
| Q34347052 | Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population |
| Q46819416 | Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation |
| Q70670290 | Omeprazole induction of cytochrome P-450IA2: the importance of selecting the appropriate human model |
| Q42002911 | Oxidative activation of proguanil and dapsone acetylation in Thai soldiers |
| Q47546933 | P450 Pharmacogenetics in Indigenous North American Populations |
| Q43777952 | Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects |
| Q70871971 | Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment |
| Q42160979 | Phenotypic differences in dextromethorphan metabolism |
| Q67969799 | Phenotyping polymorphic drug metabolism in the French Caucasian population |
| Q33921325 | Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping |
| Q79291837 | Polymorphisms and the Pocketbook: The Cost‐Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori Infection Associated with Duodenal Ulcer |
| Q42284944 | Polymorphisms in oxidative drug metabolism: relationship to food preference |
| Q34307298 | Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate |
| Q34345510 | Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark |
| Q34865832 | Proton pump inhibitors--differences emerge in hepatic metabolism |
| Q42285032 | Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism |
| Q36441521 | Role of cytochrome P450 genotype in the steps toward personalized drug therapy |
| Q46521238 | S-mephenytoin 4-hydroxylation in older Americans |
| Q47722127 | Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. |
| Q30946826 | Simultaneous enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma by liquid chromatography. |
| Q34447888 | Sparteine oxidation is practically abolished in quinidine-treated patients |
| Q40858967 | Stereoselective and isozyme-selective drug interactions |
| Q42285085 | Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype |
| Q41120052 | The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole |
| Q34358893 | The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study |
| Q34741545 | The genetic basis of variability in drug responses |
| Q39063279 | The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism |
| Q39288374 | The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women |
| Q37361919 | The pharmacokinetics of escitalopram in patients with hepatic impairment |
| Q39422300 | The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations |
| Q36175710 | The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview |
| Q73846452 | Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes |
| Q39341299 | Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers |
Search more.